Not long ago, it was taken as a given that we’d live longer than our parents – just as most of them lived longer and healthier lives than their own. But something strange has happened in the last 15 years or so. Increases in life expectancy have stalled, and there are signs it might even […]
Where has the time gone? We are now in 2025, and industry events are quickly approaching. If you are still gathering your thoughts on how best to maximise your events calendar this year, allow us to flag some of the ‘must-attend’ Healthcare conferences of Winter/Spring 2025. January is for JPM The 43rd JPM Annual Healthcare […]
2024 has been a phenomenal year for Optimum and its clients, with some spectacular successes both in and out of the clinic. Here are some of the highlights from a year that saw the life sciences industry get back on track after some challenging times. M&A Deals There was great news for Calliditas Therapeutics, one […]
Optimum’s clients pushed on with their vital research in 2024, from preclinical studies to cutting-edge oncology clinical trials. Biocomposites announced two new Phase II clinical trials of Stimulan VG, a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin, to take place in the U.S. BLADE-VG2 trial will evaluate the safety and efficacy of STIMULAN […]
2024 saw our clients raise nearly US$2 billion in what turned out to be a busy year! As we head into 2025, we hope to see the funding translate into results in the clinic, with many more financings in the pipeline. Seed Disco Pharmaceuticals (Germany) launched with a €20 million (US$21 million) seed financing to […]
